{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-035316","form_type":"8-K","ticker":"SIGA","cik":"0001010086","company_name":"SIGA TECHNOLOGIES INC","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.866324+00:00","generated_at":"2026-05-31T13:35:27.676250+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SIGA Q2 product sales $20.7M, net income $1.8M; receives $113M U.S. order in July","bullets":["Product sales $20.7M in Q2 (vs $1.3M prior year); total revenues $21.8M; net income $1.8M or $0.03 diluted EPS.","Received $113M procurement order from U.S. government for oral TPOXX in July 2024 under BARDA contract.","Delivered $18M of IV TPOXX to U.S. SNS in Q2; $3M oral TPOXX to new ASEAN customer.","Paid special cash dividend of $0.60 per share on April 11, 2024, up $0.15 from prior year.","Amendment with Meridian gives SIGA control over international promotion of oral TPOXX effective June 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-035316","json":"https://secwatch.observer/filing/0001140361-24-035316.json","markdown":"https://secwatch.observer/filing/0001140361-24-035316.md","text":"https://secwatch.observer/filing/0001140361-24-035316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1010086/000114036124035316/0001140361-24-035316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1010086/000114036124035316/ef20033337_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:35:27.676250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}